This week, Christopher A. Viehbacher, president U.S. Pharmaceuticals GlaxoSmithKline, sent a letter to the leadership in Massachusetts suggesting his firm might not invest as much in Massachusetts if “political developments” work to “devalue” its assets here.
"Some Massachusettes political leaders, meanwhile, seam to go out of their way to attach and demonize an industry that those in other parts of the country are desperate to have."
According to the Boston Herald, Glaxo Exec Blasts State the Governor and House leadership were stunned.
It’s important that the leadership of the State of Massachusetts understand the consequences of apdotion of Section 26 of S2660 to the pharmaceutical and medical device industries. And especially the bill’s negative impact on education and research in the Commonwealth of Massachusetts.